Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

SNY.US Logo

SNY.US - Current Price

$47.07

Company Information

▼
Company Name
Sanofi ADR
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
ISIN: US80105N1054
CIK: 0001121404
CUSIP: 80105N204
Currency: USD
Full Time Employees: 82,878
Phone: 33 1 53 77 40 00
Website: https://www.sanofi.com
Fiscal Year End: December
IPO Date: Jul 01, 2002
Description:

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Address:

46, avenue de la Grande Armée, Paris, France, 75017

Directors & Officers

▼
Name Title Year Born
Mr. Paul Hudson CEO & Director 1967
Mr. François-Xavier Roger Executive VP & CFO 1962
Ms. Madeleine Roach Executive VP & Head of Business Operations 1984
Mr. Thomas Kudsk Larsen Head of Investor Relations 1974
Mr. Roy Papatheodorou Executive VP & General Counsel 1978
Mr. Pierre Chancel Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing 1957
Ms. Natalie Bickford Executive VP & Chief People Officer 1970
Mr. Olivier Charmeil Executive Vice President of General Medicines 1963
Fabrizio Gaudi Head of Austrian, German & Swiss Operations NA
Mr. Felix Lauscher Head of IR North America & Asia NA

Shares Statistics

▼
Shares Outstanding: 2.42B
Shares Float: 1.10B
% Insiders: 0.10%
% Institutions: 989.30%
Short % Float: 0.36%

Valuation Metrics

▼
Enterprise Value: $124.08B
Trailing P/E: 15.61
Forward P/E: 9.74

Financial Highlights

▼
Market Cap: $115.32B
EBITDA: $12.33B
P/E Ratio: $15.61
PEG Ratio: $0.73
Book Value: $69.91
Dividend/Share: $0.00
Dividend Yield: 0.00%
Earnings/Share: $3.05
Profit Margin: 19.84%
Operating Margin: 28.73%
ROA (TTM): 4.61%
ROE (TTM): 8.84%
Revenue (TTM): $45.93B
Revenue/Share (TTM): $18.66
Earnings Growth (YOY): 2.40%
Revenue Growth (YOY): -7.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 0.83 N/A -10,000.00%
Sep 30, 2025 1.69 1.62 N/A 425.31%
Jun 30, 2025 0.91 1.00 N/A -900.00%
Mar 31, 2025 1.02 0.95 N/A 736.84%
Dec 31, 2024 0.68 0.74 N/A -810.81%
Sep 30, 2024 1.54 1.38 N/A 1,159.42%
Jun 30, 2024 0.93 0.86 N/A 813.95%
Mar 31, 2024 0.97 0.94 N/A 319.15%
Dec 31, 2023 0.89 1.50 N/A -4,066.67%
Sep 30, 2023 2.77 2.27 N/A 2,202.64%
Jun 30, 2023 0.95 1.55 N/A -3,870.97%
Mar 31, 2023 1.16 1.88 N/A -3,829.79%
Dec 31, 2022 0.87 0.90 N/A -333.33%
Sep 30, 2022 1.44 1.34 N/A 746.27%
Jun 30, 2022 0.92 0.87 N/A 574.71%
Mar 31, 2022 1.09 0.92 N/A 1,847.83%
Dec 31, 2021 0.79 0.72 N/A 972.22%
Sep 30, 2021 1.28 1.17 N/A 940.17%
Jun 30, 2021 0.83 0.75 N/A 1,066.67%
Mar 31, 2021 0.97 0.78 N/A 2,435.90%
Dec 31, 2020 0.73 0.69 N/A 579.71%
Sep 30, 2020 1.07 1.09 N/A -183.49%
Jun 30, 2020 0.71 0.65 N/A 923.08%
Mar 31, 2020 0.90 0.79 N/A 1,392.41%
Dec 31, 2019 0.74 0.69 N/A 724.64%
Sep 30, 2019 0.96 0.96 N/A 0.00%
Jun 30, 2019 0.66 0.70 N/A -571.43%
Mar 31, 2019 0.81 0.75 N/A 800.00%
Dec 31, 2018 0.63 0.65 N/A -307.69%
Sep 30, 2018 1.07 0.95 N/A 1,263.16%
Jun 30, 2018 0.74 0.72 N/A 277.78%
Mar 31, 2018 0.77 0.69 N/A 1,159.42%
Dec 31, 2017 0.62 0.70 N/A -1,142.86%
Sep 30, 2017 1.00 0.96 N/A 416.67%
Jun 30, 2017 0.74 0.76 N/A -263.16%
Mar 31, 2017 0.75 0.70 N/A 714.29%
Dec 31, 2016 0.67 0.66 N/A 151.52%
Sep 30, 2016 1.00 0.80 N/A 2,500.00%
Jun 30, 2016 0.74 0.72 N/A 277.78%
Mar 31, 2016 0.74 0.77 N/A -389.61%
Dec 31, 2015 0.82 0.71 N/A 1,549.30%
Sep 30, 2015 0.90 0.88 N/A 227.27%
Jun 30, 2015 0.55 N/A N/A N/A
Mar 31, 2015 0.00 0.00 N/A N/A
Dec 31, 2014 0.00 0.00 N/A N/A
Dec 31, 2013 0.93 1.28 N/A -2,734.38%
Dec 31, 2012 0.77 1.55 N/A -5,032.26%
Sep 30, 2012 1.05 1.92 N/A -4,531.25%
Dec 31, 2011 1.05 1.59 N/A -3,396.23%
Sep 30, 2011 1.26 1.21 N/A 413.22%
Dec 31, 2009 1.01 2.06 N/A -5,097.09%
Dec 31, 2008 0.83 1.79 N/A -5,363.13%
Mar 31, 2008 1.06 5.42 N/A -8,044.28%
Dec 31, 2007 0.79 0.80 N/A -125.00%
Sep 30, 2007 0.94 0.85 N/A 1,058.82%
Jun 30, 2007 0.84 0.89 N/A -561.80%
Mar 31, 2007 1.03 0.87 N/A 1,839.08%
Dec 31, 2006 0.66 0.59 N/A 1,186.44%
Sep 30, 2006 0.80 0.71 N/A 1,267.61%
Jun 30, 2006 0.84 0.78 N/A 769.23%
Mar 31, 2006 0.97 0.88 N/A 1,022.73%
Dec 31, 2005 0.64 0.63 N/A 158.73%
Sep 30, 2005 0.88 0.73 N/A 2,054.79%
Jun 30, 2005 0.73 0.68 N/A 735.29%
Mar 31, 2005 0.70 0.65 N/A 769.23%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $7.44B $N/A $132.80B $54.94B $77.51B
2023-12-31 $8.71B $N/A $126.46B $52.11B $74.04B
2022-12-31 $12.74B $N/A $126.72B $51.57B $74.78B
2021-12-31 $10.10B $N/A $120.24B $51.21B $68.68B
2020-12-31 $13.92B $N/A $114.41B $51.16B $63.11B
2019-12-31 $9.43B $N/A $112.63B $53.40B $59.06B
2018-12-31 $6.93B $N/A $111.41B $52.37B $58.88B
2017-12-31 $10.32B $N/A $99.81B $41.57B $58.07B
2016-12-31 $10.27B $N/A $104.67B $46.95B $57.55B
2015-12-31 $9.15B $N/A $102.32B $44.11B $58.05B
2014-12-31 $7.34B $N/A $97.39B $41.12B $56.12B
2013-12-31 $8.26B $N/A $96.06B $39.02B $56.90B
2012-12-31 $6.38B $N/A $100.41B $42.94B $57.33B
2011-12-31 $1.93B $N/A $100.67B $44.30B $56.20B
2010-12-31 $5.77B $N/A $85.26B $31.98B $53.10B
2009-12-31 $689.00M $N/A $80.05B $31.60B $48.19B
2008-12-31 $540.00M $N/A $71.99B $26.92B $44.87B
2007-12-31 $1.71B $N/A $69.00B $24.28B $44.54B
2006-12-31 $1.15B $N/A $74.27B $28.45B $45.60B
2005-12-31 $1.25B $N/A $86.95B $40.63B $46.13B
2004-12-31 $1.84B $N/A $85.41B $43.88B $41.06B
2003-12-31 $151.66M $N/A $9.73B $3.40B $6.31B
2002-12-31 $143.90M $N/A $9.47B $3.41B $6.04B
2001-12-31 $123.00M $N/A $9.97B $4.18B $5.77B
2000-12-31 $207.00M $N/A $7.85B $3.51B $4.30B
1999-12-31 $202.00M $N/A $6.82B $3.21B $3.58B

Watchlist

0

No stocks in watchlist